Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon Feb 02, 2023 2:10am
107 Views
Post# 35261415

RE:RE:WTF

RE:RE:WTFI still think Sirona had no choice in the matter of how large the upfront payment was. Abbvie told them to take it or shove it.    
forhandlaren wrote: Daily bids are removed after the close and can give misleading impression.

However, I'm concerned - not so much for single digits because most of the sellers triggers a loss, but lack expectations are reflected.

The science are usually successful and results from two important clinical studies are expected within a few weeks so I guess the rationale is that the market doesn't care because lack of trust that Howard can turn this into profitable deals.

One big mistake was to prioritize a presumed nice royalty over an impressive up-front. The negative consequence could be less revenue in the long run, but a much stronger company and positive momentum. I would have choosen the latter... Anti-aging is the real block buster!


<< Previous
Bullboard Posts
Next >>